表紙
市場調査レポート

Novavax, Inc.:パイプライン製品の分析

Novavax, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 219825
出版日 ページ情報 英文 48 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
Novavax, Inc.:パイプライン製品の分析 Novavax, Inc. - Product Pipeline Review - 2015
出版日: 2015年06月17日 ページ情報: 英文 48 Pages
概要

Novavax, Inc.は、臨床病期のバイオ製薬企業で、広範囲の感染性疾患に対処するワクチンやアジュバントの創出と開発を専門としています。

当レポートでは、Novavax, Inc.による治療用パイプライン製品の開発状況について調査分析し、研究・開発の概要、パイプライン製品の概要、治験の段階別の製品の概要、薬剤プロファイル、パイプライン分析、企業情報などについて、体系的な情報を提供しています。

目次

Novavax, Inc.の概要

Novavax, Inc. - 研究・開発の概要

  • 主要治療分野

Novavax, Inc. - パイプライン検証

  • パイプライン製品:開発段階別
  • パイプライン製品 - 単独療法
  • パイプライン製品 - 併用療法
  • パイプライン製品 - 提携製品
  • パイプライン製品 - アウトライセンス製品

Novavax, Inc. - パイプライン製品の概要

  • パイプライン製品 - 治験段階のパイプライン製品
  • パイプライン製品 - 初期段階のパイプライン製品

Novavax, Inc. - 薬剤プロファイル

  • H1N1-2009 VLP Vaccine
  • Quadrivalent Seasonal Influenza Virus-Like Particle Vaccine
  • Respiratory Syncytial Virus Vaccine
  • Trivalent Seasonal Influenza VLP Vaccine
  • H5N1 VLP Influenza Vaccine
  • H7N9 VLP Influenza Vaccine
  • E-Selectin Tolerogen
  • MERS-CoV Vaccine
  • Respiratory Syncytical Virus Fusion + Seasonal Influenza Virus-Like Particle
  • SARS-CoV Vaccine
  • Vaccine For Rabies
  • Varicella Zoster Virus Vaccine

Novavax, Inc. - パイプライン分析

  • パイプライン製品:標的別
  • パイプライン製品:投与経路別
  • パイプライン製品:分子タイプ別

Novavax, Inc. - パイプライン製品の最新動向

Novavax, Inc. - 休止状態のプロジェクト

Novavax, Inc. - 財務諸表

Novavax, Inc. - 所在地と子会社

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07176CDB

Summary

Global Markets Direct's, 'Novavax, Inc. - Product Pipeline Review - 2015', provides an overview of the Novavax, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Novavax, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Novavax, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Novavax, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Novavax, Inc.'s pipeline products

Reasons to buy

  • Evaluate Novavax, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Novavax, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Novavax, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Novavax, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Novavax, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Novavax, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Novavax, Inc. Snapshot
    • Novavax, Inc. Overview
    • Key Information
    • Key Facts
  • Novavax, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Novavax, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Novavax, Inc. - Pipeline Products Glance
    • Novavax, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Novavax, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Novavax, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Novavax, Inc. - Drug Profiles
    • influenza (trivalent) virus like particle vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza (quadrivalent) virus like particle vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain H7N9] (monovalent) virus like particle vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • respiratory syncytial virus vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rabies vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ebola vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MERS-CoV Vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • respiratory syncytical virus + influenza vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SARS-CoV Vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Novavax, Inc. - Pipeline Analysis
    • Novavax, Inc. - Pipeline Products by Target
    • Novavax, Inc. - Pipeline Products by Route of Administration
    • Novavax, Inc. - Pipeline Products by Molecule Type
  • Novavax, Inc. - Recent Pipeline Updates
  • Novavax, Inc. - Dormant Projects
  • Novavax, Inc. - Company Statement
  • Novavax, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Novavax, Inc., Key Information
  • Novavax, Inc., Key Facts
  • Novavax, Inc. - Pipeline by Indication, 2015
  • Novavax, Inc. - Pipeline by Stage of Development, 2015
  • Novavax, Inc. - Monotherapy Products in Pipeline, 2015
  • Novavax, Inc. - Combination Treatment Modalities in Pipeline, 2015
  • Novavax, Inc. - Partnered Products in Pipeline, 2015
  • Novavax, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Novavax, Inc. - Phase III, 2015
  • Novavax, Inc. - Phase II, 2015
  • Novavax, Inc. - Phase I, 2015
  • Novavax, Inc. - Preclinical, 2015
  • Novavax, Inc. - Pipeline by Target, 2015
  • Novavax, Inc. - Pipeline by Route of Administration, 2015
  • Novavax, Inc. - Pipeline by Molecule Type, 2015
  • Novavax, Inc. - Recent Pipeline Updates, 2015
  • Novavax, Inc. - Dormant Developmental Projects,2015
  • Novavax, Inc., Other Locations
  • Novavax, Inc., Subsidiaries

List of Figures

  • Novavax, Inc. - Pipeline by Top 10 Indication, 2015
  • Novavax, Inc. - Pipeline by Stage of Development, 2015
  • Novavax, Inc. - Monotherapy Products in Pipeline, 2015
  • Novavax, Inc. - Partnered Products in Pipeline, 2015
  • Novavax, Inc. - Pipeline by Top 10 Target, 2015
  • Novavax, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Novavax, Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top